3 RTI Health Solutions, Raleigh, NC, USA OBJECTIVES: Prospective Obesity Cohort of Economic Evaluation Determinants (PROCEED) is an ongoing longitudinal cohort of overweight subjects aged 35-75 intending to lose weight. The primary objective is to compare health care consumptions and costs in subjects who are overweight (BMI 25 kg/m 2 ) with or without abdominal obesity (AO) (waist circumference 102 cm for male and 88 cm for female) versus non-overweight subjects (BMI 20-24 kg/m 2 ). METHODS: Recruitment started in the US in November 2004. Internet-based follow-up assessments will occur monthly for weight and waist circumference of overweight subjects, and quarterly for health and economic outcomes (hospitalizations, ER, outpatient services, prescription medications for selected conditions) of all subjects. RESULTS: Baseline analysis was conducted on non-overweight subjects (100) and overweight subjects with waist circumference measurement (293 without AO and 674 with AO). Health care resource costs per participant were calculated by applying unit costs to health care resource consumption reported at baseline during the past 3 months. Mean costs in overweight subjects with AO were almost twice those in overweight subjects without AO ($132 versus $72), and over 3.5 times those of controls ($37). Overweight subjects with AO compared with those without AO were more likely to have reported current prescriptions for depression (21.1% versus 12.3%) and diabetes (11.9% versus 4.4%). The percentage of subjects with zero costs was 23% and 31% in the overweight group (AO and non AO, respectively) compared with 39% in the control group. CON-CLUSION: Abdominal obesity appears to be associated with markedly increase costs, especially those related to prescriptions. As the PROCEED cohort progresses, further collection and analyses of economic outcomes will allow a deeper understanding of the impact of abdominal obesity on costs and health care consumptions. (ATTEMPT) is a prospective multinational observational longitudinal cohort designed to examine the natural course of successive smoking cessation attempts and their impact on health and economic outcomes. In order to evaluate the validity of the data collected via the Internet, self-reported weight and waist circumference (WC) were compared to in-home assessed measurements. METHODS: Subjects were recruited from existing Internet consumer panels Harris Interactive in 5 countries: Canada, France, Spain, the UK and the US. Subjects had to be aged 35-65 years, smoke at least 5 cigarettes per day, and intend to quit smoking. Assessments included questions on smoking status, health conditions, medical resource use and quality of life. Study participants were mailed at home standardized weight scales and tape measures with instructions. Inhome assessments were performed by a health professional in a random sample of the US subjects right after they completed the quarterly Internet survey. RESULTS: Out of the 4647 subjects included at baseline, 3242 (70%) completed the 3-month assessments and 2917 (63%) completed the 6-month assessments. In the US, 1147 (78%) subjects agreed to the in-home visit and 200 visits were conducted according to protocol specifications in December 2004 and January 2005. No statistically significant difference and high positive correlations were found between self-reported and observed weight (mean ± SD difference: underself-reported +0.6 ± 6.3 kg; correlation: 0.95) and waist circumference (over-self-reported -0.3 ± 10.3 cm; 0.81). The distribution of demographic characteristics for the assessed sample was similar to characteristics of the remaining cohort. CONCLUSIONS: Based on good correlations between in-home visit and self-reporting on the web in the US, Internet is a reliable tool to collect health related data. As the ATTEMPT cohort progresses, this analysis will be reassessed with a greater sample size and further explored in other countries. In both women and men, the highest EQ5D index values (best QoL) was evident in overweight people with a low WC. A reduction in WC in obese people resulted in a greater gain in utility than the same change in normal or overweight people. Use of both BMI and WC, rather than a single measure of obesity, provided a more precise prediction of health-related utility. Utility varied more widely as a function of waist circumference in higher BMI categories.
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POB9 EVALUATION OF THE ASSOCIATION BETWEEN BODY MASS INDEX, WAIST CIRCUMFERENCE AND HEALTH-RELATED UTILITY (EQ5D)
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POB10 VALIDATION OF A PATIENT-REPORTED OUTCOMES QUESTIONNAIRE FOR ASSESSING POSITIVE WELL-BEING ASSOCIATED WITH BEHAVIORAL CHANGES
Mesrobian X 1 , Mertzanis P 1 , Dard S 2 1 Mapi Values USA, Boston, MA, USA; 2 Mapi Values, Lyon, France Based on 31 concept-elicitation interviews of former smokers and individuals who wanted to lose weight, a questionnaire was developed simultaneously in three languages (French, US-English and US-Spanish). Draft items were generated in each language and culturally adapted into Spain-Spanish and UK-English. Face validity was assessed through 30 cognitive debriefing interviews; resulting in a 27-item questionnaire. OBJECTIVE: To validate a questionnaire that investigates the positive well-being associated with behavioral changes in adults. METHODS: The psychometric properties of the questionnaire were examined in US-English, US-Spanish and French through a stand-alone study in former smokers and individuals who wanted to lose weight. RESULTS: Based on an initial Principal Component Analysis (PCA) and item-item correlation analysis, 18 items were retained. A final PCA indicated that the questionnaire encompassed five dimensions: Serenity; Healthy Lifestyle, Support from Others, SelfConfidence, and Social Life. The questionnaire surpassed the threshold for internal consistency reliability for all dimensions and globally (Cronbach's alpha > 0.8) in both behavioral changes and in all languages. All items surpassed the criterion for itemconvergent validity and item-discriminant validity was satisfactory for 17/18 items. Correlations between the questionnaire and the Psychological General Well-Being index (PGWBi) scores confirmed its validity and indicated that it supplements information obtained through the PGWBi. Known-groups validity was satisfactory in individuals who wanted to lose weight based on the amount of weight lost, BMI reduction and number of weight loss attempts, but was inconclusive in former smokers because the abstinence status and the discontinuation of smoking cessation aids were not confirmed. CONCLUSION: Results support the reliability and validity of this questionnaire making it a useful tool for determining the positive well-being associated with behavioral changes. The questionnaire is currently undergoing additional validity testing in a population where smoking status is assessed. Patients were separated into three groups according to the VA at start PHD (AVFgroup): Group 1(G1) having an adequate functioning AVF before initiating HD; group 2(G2) not having an AVF at the start of HD, but having it before three months; group 3(G3) using catheters during the first three months. Patients who had a delayed nephrology referral, those who suddenly started PHD and those with Diabetes mellitus were excluded because these are mortality risk factors. RESULTS: There were no significant differences between the three groups with respect to initial variables of patients: age (p = 0.10), sex (p = 0.45), diagnostic of renal disease (p = 0.24) and CCI (p = 0.76). G1 patients had lower "de novo" morbidity and less hospitalisations (p = 0.000). A logistic regression was applied with morbidity and hospitalisations as dependent variables and age, sex, CCI and AVFgroup as co-variables: G2 and G3 were independently associated with higher morbidity and hospitalisations (p < 0.01). KaplanMeier analysis showed that G1 had better survival than G2 and G3 (33 months vs. 27 and 24); and patients without morbidity had better survival than those with. The Cox Regression (time dependent model) analysis showed that not having an adequate AVF at start of PHD (G2 and G3) reduced survival (RR:11.32; CI:1.06-120.6). Cost-effectiveness analysis showed that G1 patients with respect to G2 and G3 had better survival and lower cost per live gained month. CONCLUSIONS: "De novo" morbidity caused by not having an adequate AVF at start of PHD considerably decreases survival and implies higher cost.
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